

**IN THE CLAIMS:****Replace claims 1, 3-20, and 23-24 as filed with amended claims 1, 3-20, and 23-24.****Cancel claims 2, 21, and 22. Add new claims 25 and 26.**

Sub  
RI  
AI

1. (Amended) An oral pharmaceutical dosage form comprising a core material coated with a semipermeable membrane, wherein:

the core material comprises an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, *S*-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable excipients;

the membrane comprises a water-insoluble polymer and a modifying agent and is able to disrupt; and the dosage form is not enteric coated.

3. (Amended) The dosage form according to claim 1, wherein the active ingredient is omeprazole.

4. (Amended) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of omeprazole having a crystallinity of more than 70% as determined by X-ray powder diffraction.

5. (Amended) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of *S*-omeprazole.

6. (Amended) The dosage form according to claim 1, wherein the core material comprises a sugar sphere layered with a suspension or solution of the active ingredient, one or more alkaline additives, one or more swelling agents and optionally pharmaceutically acceptable excipients.

7. (Amended) The dosage form according to claim 1, wherein the dosage form comprises individual pellets of the core material coated with the semipermeable membrane.

8. (Amended) The dosage form according to claim 1, wherein the core material further comprises an osmotic agent.

9. (Amended) The dosage form according to claim 1, wherein the alkaline additive gives a pH of not less than 8.5 when measured in a 2% w/w water solution/dispersion with a pH-measuring electrode.

10. (Amended) The dosage form according to claim 9, wherein the alkaline additive is selected from the group consisting of disodium hydrogen phosphate, trisodium phosphate, arginine and talc.

11. (Amended) The dosage form according to claim 1, wherein the alkaline additive is present in an amount of approximately 5 to 35% by weight of the core material excluding the weight of an optional sugar sphere.

12. (Amended) The dosage form according to claim 1, wherein the alkaline additive is present in an amount of 15 to 35% by weight of the core material excluding the weight of an optional sugar sphere.

13. (Amended) The dosage form according to claim 1, wherein the swelling agent is selected from the group consisting of crosslinked polyvinyl pyrrolidone, crosslinked sodium carboxymethylcellulose, sodium starch glycolate and low-substituted hydroxypropyl cellulose (L-HPC).

14. (Amended) The dosage form according to claim 1, wherein the swelling agent is present in an amount of approximately 20 to 60% by weight of the core material excluding the weight of an optional sugar sphere.

15. (Amended) The dosage form according to claim 1, wherein the swelling agent is present in an amount of 30 to 50% by weight of the core material excluding the weight of an optional sugar sphere.

16. (Amended) The dosage form according to claim 1, wherein the modifying agent is talc or fumed silica.

17. (Amended) The dosage form according to claim 1, wherein the water insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, polyvinyl acetate, and ammonio methacrylate copolymer type A and type B.

18. (Amended) The dosage form according to claim 1, wherein the water insoluble polymer is present in an amount of approximately 3-30% by weight of the core material.

19. (Amended) The dosage form according to claim 1, wherein the modifying agent and water insoluble polymer are in a ratio of between 90:10 and 50:50.

20. (Amended) A process for the manufacture of a dosage form as defined in claim 1, comprising forming a core material comprising an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, *S*-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable

Sub  
B2  
cont.  
AR

excipients, and coating the core material with a semipermeable membrane, wherein the dosage form has no enteric coating.

AB

23. (Amended) A method for improving inhibition of gastric acid secretion which comprises administering to a patient in need thereof, an oral pharmaceutical dosage form according to any one of claims 1 or 3-19.

24. (Amended) A method for improving the therapeutic effect in the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to a patient in need thereof, an oral pharmaceutical dosage form according to any one of claims 1 or 3-19.

25. (New) An oral dosage form according to any one of claims 1 or 3-19 filled in a capsule.

26. (New) An oral dosage form according to any one of claims 1 or 3-19 compressed into a multiple unit tableted dosage form, optionally comprising tablet excipients.